Developer docs
API playgroundTry for free, no card

Search company profiles

Soufflé Therapeutics

Full company profile

uuid0004z77

Namestring
Soufflé Therapeutics
Legal namestring
Soufflé Therapeutics, Inc.
Websiteurl
souffletx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Soufflé Therapeutics is a pre-clinical biotechnology company developing a cell-selective ligand platform for targeted delivery of siRNA-based genetic medicines. The company's core technology engineers cell-specific ligands that ferry siRNA payloads across cell membranes and into precise target cells — including cardiomyocytes and skeletal muscle cells — addressing the long-standing limitation of conventional lipid nanoparticle (LNP) and GalNAc delivery systems that primarily reach the liver. The platform integrates three proprietary capabilities: cell-specific receptor identification, ligand optimization for binding affinity and selectivity, and potent siRNA engineering. Soufflé is designed as a platform replicable across cell types rather than a single-asset company.

The company is headquartered in Watertown, MA, and was founded in 2021 by a scientific team including Robert Langer, Daniel Anderson, Victor Kotelianski, Marino Zerial, and Bradley Pentelute — leaders in drug delivery, RNA therapeutics, and intracellular trafficking. Its initial clinical programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated dilated cardiomyopathy, with first-in-human trials planned to begin in 2026. The company employs 51–100 people and has raised capital and executed collaboration agreements exceeding $3.5 billion in aggregate, including a $200 million financing in January 2025 led by Bessemer Venture Partners.

Soufflé commercializes its pipeline through licensing and co-development partnerships with major pharmaceutical companies rather than direct product sales. Named partners include Bayer (global licensing agreement for a heart-targeted siRNA therapy announced January 2026), AbbVie, Amgen, and Novo Nordisk. Revenue mechanics consist of upfront payments, development and commercial milestones, and future royalties on approved products, consistent with a pre-clinical biotech operating model. The company also benefits from strategic equity investment by Leaps by Bayer and a syndicate of top-tier healthcare and venture investors including Polaris Partners, ARCH Venture Partners, Vida Ventures, and Temasek.

Short descriptiontext

Soufflé Therapeutics is a pre-clinical biotech developing cell-specific ligand technology for targeted siRNA delivery beyond the liver, with lead programs in FSHD and PLN cardiomyopathy entering clinical trials in 2026 and a licensing-based business model with partners including Bayer, AbbVie, Amgen, and Novo Nordisk.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
siRNA therapeutics, targeted genetic medicines, cell-specific delivery, RNA-based therapeutics, cell-selective ligands
Industry3 codes
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
RNA-based Genetic Medicines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Soufflé develops proprietary siRNA medicines and commercializes them through licensing agreements and co-development partnerships with large pharmaceutical companies, generating revenue through upfront payments, milestone payments, and royalties on approved products.

souffletx.com
2Future Product Sales
TypeSubscription Recurring
Description

As the company advances its pipeline toward clinical trials and potential commercial launch, future revenue may be generated through product sales for its targeted genetic medicines addressing rare genetic diseases and broader metabolic disorders.

souffletx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Soufflé Therapeutics engineers cell-specific ligands to deliver siRNA-based genetic medicines precisely across cell membranes into target cells such as cardiomyocytes and skeletal muscle cells. The company combines proprietary technologies for cell-specific receptor identification, ligand optimization, and potent siRNA engineering to develop therapies addressing rare genetic diseases and broader metabolic disorders. Initial programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated cardiomyopathies, with clinical trials planned to begin in 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First clinical trials planned to begin in 2026 for FSHD and PLN-associated cardiomyopathy programs
Product overview1 text field

Soufflé Therapeutics is a biotech company that has developed a unified platform combining proprietary technologies for identification of cell-specific receptors, ligand optimization, and potent siRNA engineering to create cell-selective genetic medicines. The company's core technology enables precise delivery of siRNA-based therapies across cell membranes to specific target cells. Soufflé's initial therapeutic programs include siRNA therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies targeting PLN gene mutations. A strategic collaboration with Bayer focuses on developing a heart-targeted siRNA therapy for dilated cardiomyopathy. The company is advancing clinical trials in 2026 for its lead programs while building a diversified pre-clinical pipeline across multiple cell and tissue types.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Bayer and Soufflé Therapeutics announced a strategic collaboration and global licensing agreement to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy. The collaboration leverages Soufflé's cell-selective ligand technology to deliver genetic medicines precisely to cardiomyocytes, addressing challenges in siRNA delivery such as off-target effects and frequent dosing. This partnership marks Bayer's entry into the siRNA therapeutics field and strengthens its cardiovascular portfolio. The collaboration builds on Bayer's prior investment in Soufflé through Leaps by Bayer.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Soufflé Therapeutics has a collaboration relationship with AbbVie as one of its pharma partners. The partnership is part of Soufflé's broader strategy to work with leading pharmaceutical companies dedicated to creating medicines.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Soufflé Therapeutics has a collaboration relationship with Amgen as one of its pharma partners. The partnership is part of Soufflé's strategy to partner with pharmaceutical companies dedicated to creating medicines.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Soufflé Therapeutics has a collaboration relationship with Novo Nordisk as one of its pharma partners, particularly in the area of metabolic disorders.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical leader in metabolic disorders and rare disease (with Dicerna siRNA acquisition). Comparable as both a strategic partner of Soufflé in metabolic disease programs and a competitor in cardiometabolic nucleic-acid therapeutics.

TypeDirect peer
Description

In vivo gene editing company targeting cardiovascular disease (e.g., PCSK9 for familial hypercholesterolemia). Comparable because Soufflé's PLN cardiomyopathy program targets an analogous cardiovascular indication using a different nucleic-acid modality, and Verve's Ellen Rohde and Victoria Bartlett both joined Soufflé's leadership.

TypeEmerging player
Description

Clinical-stage nucleic-acid therapeutics company developing stereopure oligonucleotides for rare and cardiometabolic diseases (e.g., WVE-006 for alpha-1 antitrypsin deficiency). Comparable as a platform-based oligonucleotide company pursuing extrahepatic tissues including muscle.

TypeDirect peer
Description

In vivo CRISPR/Cas9 gene editing company with LNP-based extrahepatic delivery programs (e.g., NTLA-2002 for HAE). Comparable as a nucleic-acid therapeutics company pursuing extrahepatic in vivo delivery to muscle and other tissues, sharing personnel pedigree (Soufflé's Ellen Rohde pioneered LNP biodistribution at Intellia).

TypeDirect peer
Description

Clinical-stage siRNA company with multiple extrahepatic delivery platforms (TRiM) targeting muscle, lung, CNS, and adipose tissue. Closely comparable to Soufflé because both are extending siRNA beyond the liver to tissues like cardiomyocytes and skeletal muscle — the exact cell types Soufflé targets.

TypeBroad incumbent
Description

Established antisense oligonucleotide (ASO) therapeutics company with multiple approved drugs (Spinraza, Tegsedi, Wainua). Directly comparable to Soufflé in nucleic-acid-based gene-silencing therapeutics and is a natural incumbent for genetic cardiometabolic and rare disease indications.

TypeBroad incumbent
Description

Clinical/commercial-stage gene editing company with both ex vivo (CASGEVY) and in vivo (cardiovascular) programs. Comparable to Soufflé as an in vivo nucleic-acid medicines company; Daniel Anderson co-founded CRISPR Therapeutics, and several Soufflé leaders (Bogorad, Sun, Bartlett) previously worked there.

TypeDirect peer
Description

Leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, inclisiran/Leqvio) pioneering GalNAc-conjugate delivery to hepatocytes. Most directly comparable peer given Soufflé's co-founder Victor Kotelianski was Alnylam's founding SVP and co-invented inclisiran, and both compete in siRNA-based genetic medicines.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing gene therapies and small molecules for cardiomyopathies and heart failure. Comparable to Soufflé's PLN cardiomyopathy program given overlapping cardiac indication and rare genetic heart disease focus.

TypeBroad incumbent
Description

Commercial-stage genetic medicines company focused on Duchenne muscular dystrophy and rare neuromuscular diseases. Comparable to Soufflé in rare muscle disease focus (FSHD) and nucleic-acid/genetic medicine modality; Soufflé's VP Clinical Development (Herb Stevenson) led multiple Sarepta BLA programs including AMONDYS 45.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Soufflé Therapeutics

RNA-based Genetic Medicinessouffletx.com

Soufflé Therapeutics is a pre-clinical biotech developing cell-specific ligand technology for targeted siRNA delivery beyond the liver, with lead programs in FSHD and PLN cardiomyopathy entering clinical trials in 2026 and a licensing-based business model with partners including Bayer, AbbVie, Amgen, and Novo Nordisk.

What Soufflé Therapeutics does

Soufflé Therapeutics is a pre-clinical biotechnology company developing a cell-selective ligand platform for targeted delivery of siRNA-based genetic medicines. The company's core technology engineers cell-specific ligands that ferry siRNA payloads across cell membranes and into precise target cells — including cardiomyocytes and skeletal muscle cells — addressing the long-standing limitation of conventional lipid nanoparticle (LNP) and GalNAc delivery systems that primarily reach the liver. The platform integrates three proprietary capabilities: cell-specific receptor identification, ligand optimization for binding affinity and selectivity, and potent siRNA engineering. Soufflé is designed as a platform replicable across cell types rather than a single-asset company.

The company is headquartered in Watertown, MA, and was founded in 2021 by a scientific team including Robert Langer, Daniel Anderson, Victor Kotelianski, Marino Zerial, and Bradley Pentelute — leaders in drug delivery, RNA therapeutics, and intracellular trafficking. Its initial clinical programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated dilated cardiomyopathy, with first-in-human trials planned to begin in 2026. The company employs 51–100 people and has raised capital and executed collaboration agreements exceeding $3.5 billion in aggregate, including a $200 million financing in January 2025 led by Bessemer Venture Partners.

Soufflé commercializes its pipeline through licensing and co-development partnerships with major pharmaceutical companies rather than direct product sales. Named partners include Bayer (global licensing agreement for a heart-targeted siRNA therapy announced January 2026), AbbVie, Amgen, and Novo Nordisk. Revenue mechanics consist of upfront payments, development and commercial milestones, and future royalties on approved products, consistent with a pre-clinical biotech operating model. The company also benefits from strategic equity investment by Leaps by Bayer and a syndicate of top-tier healthcare and venture investors including Polaris Partners, ARCH Venture Partners, Vida Ventures, and Temasek.

Soufflé Therapeutics firmographics

Firmographics
Name
Soufflé Therapeutics
Legal name
Soufflé Therapeutics, Inc.
Website
https://souffletx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Soufflé Therapeutics is a pre-clinical biotech developing cell-specific ligand technology for targeted siRNA delivery beyond the liver, with lead programs in FSHD and PLN cardiomyopathy entering clinical trials in 2026 and a licensing-based business model with partners including Bayer, AbbVie, Amgen, and Novo Nordisk.
Ownership category
akta.pro rank

Soufflé Therapeutics industry classification

Industry
Product category
RNA-based Genetic Medicines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • SiRNA therapeutics
  • Targeted genetic medicines
  • Cell-specific delivery
  • RNA-based therapeutics
  • Cell-selective ligands

Where Soufflé Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Soufflé Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Licensing and Co-development Agreements: Soufflé develops proprietary siRNA medicines and commercializes them through licensing agreements and co-development partnerships with large pharmaceutical companies, generating revenue through upfront payments, milestone payments, and royalties on approved products.
  2. Future Product Sales: As the company advances its pipeline toward clinical trials and potential commercial launch, future revenue may be generated through product sales for its targeted genetic medicines addressing rare genetic diseases and broader metabolic disorders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Soufflé Therapeutics product offering

Product offering

Core offering

Soufflé Therapeutics engineers cell-specific ligands to deliver siRNA-based genetic medicines precisely across cell membranes into target cells such as cardiomyocytes and skeletal muscle cells. The company combines proprietary technologies for cell-specific receptor identification, ligand optimization, and potent siRNA engineering to develop therapies addressing rare genetic diseases and broader metabolic disorders. Initial programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated cardiomyopathies, with clinical trials planned to begin in 2026.

Product overview

Soufflé Therapeutics is a biotech company that has developed a unified platform combining proprietary technologies for identification of cell-specific receptors, ligand optimization, and potent siRNA engineering to create cell-selective genetic medicines. The company's core technology enables precise delivery of siRNA-based therapies across cell membranes to specific target cells. Soufflé's initial therapeutic programs include siRNA therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies targeting PLN gene mutations. A strategic collaboration with Bayer focuses on developing a heart-targeted siRNA therapy for dilated cardiomyopathy. The company is advancing clinical trials in 2026 for its lead programs while building a diversified pre-clinical pipeline across multiple cell and tissue types.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • First clinical trials planned to begin in 2026 for FSHD and PLN-associated cardiomyopathy programs

Companies that use Soufflé Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Soufflé Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Soufflé Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • BayercoreStrategic or Co-development Partner · 8 January 2026Bayer and Soufflé Therapeutics announced a strategic collaboration and global licensing agreement to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy. The collaboration leverages Soufflé's cell-selective ligand technology to deliver genetic medicines precisely to cardiomyocytes, addressing challenges in siRNA delivery such as off-target effects and frequent dosing. This partnership marks Bayer's entry into the siRNA therapeutics field and strengthens its cardiovascular portfolio. The collaboration builds on Bayer's prior investment in Soufflé through Leaps by Bayer.
  • AbbViemajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with AbbVie as one of its pharma partners. The partnership is part of Soufflé's broader strategy to work with leading pharmaceutical companies dedicated to creating medicines.
  • AmgenmajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with Amgen as one of its pharma partners. The partnership is part of Soufflé's strategy to partner with pharmaceutical companies dedicated to creating medicines.
  • Novo NordiskmajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with Novo Nordisk as one of its pharma partners, particularly in the area of metabolic disorders.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Soufflé Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global pharmaceutical leader in metabolic disorders and rare disease (with Dicerna siRNA acquisition). Comparable as both a strategic partner of Soufflé in metabolic disease programs and a competitor in cardiometabolic nucleic-acid therapeutics.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved drugs (Spinraza, Tegsedi, Wainua). Directly comparable to Soufflé in nucleic-acid-based gene-silencing therapeutics and is a natural incumbent for genetic cardiometabolic and rare disease indications.
  • CRISPR Therapeutics: Clinical/commercial-stage gene editing company with both ex vivo (CASGEVY) and in vivo (cardiovascular) programs. Comparable to Soufflé as an in vivo nucleic-acid medicines company; Daniel Anderson co-founded CRISPR Therapeutics, and several Soufflé leaders (Bogorad, Sun, Bartlett) previously worked there.
  • Sarepta Therapeutics: Commercial-stage genetic medicines company focused on Duchenne muscular dystrophy and rare neuromuscular diseases. Comparable to Soufflé in rare muscle disease focus (FSHD) and nucleic-acid/genetic medicine modality; Soufflé's VP Clinical Development (Herb Stevenson) led multiple Sarepta BLA programs including AMONDYS 45.

Direct peers

  • Verve Therapeutics: In vivo gene editing company targeting cardiovascular disease (e.g., PCSK9 for familial hypercholesterolemia). Comparable because Soufflé's PLN cardiomyopathy program targets an analogous cardiovascular indication using a different nucleic-acid modality, and Verve's Ellen Rohde and Victoria Bartlett both joined Soufflé's leadership.
  • Intellia Therapeutics: In vivo CRISPR/Cas9 gene editing company with LNP-based extrahepatic delivery programs (e.g., NTLA-2002 for HAE). Comparable as a nucleic-acid therapeutics company pursuing extrahepatic in vivo delivery to muscle and other tissues, sharing personnel pedigree (Soufflé's Ellen Rohde pioneered LNP biodistribution at Intellia).
  • Arrowhead Pharmaceuticals: Clinical-stage siRNA company with multiple extrahepatic delivery platforms (TRiM) targeting muscle, lung, CNS, and adipose tissue. Closely comparable to Soufflé because both are extending siRNA beyond the liver to tissues like cardiomyocytes and skeletal muscle — the exact cell types Soufflé targets.
  • Alnylam Pharmaceuticals: Leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, inclisiran/Leqvio) pioneering GalNAc-conjugate delivery to hepatocytes. Most directly comparable peer given Soufflé's co-founder Victor Kotelianski was Alnylam's founding SVP and co-invented inclisiran, and both compete in siRNA-based genetic medicines.

Emerging players

  • Wave Life Sciences: Clinical-stage nucleic-acid therapeutics company developing stereopure oligonucleotides for rare and cardiometabolic diseases (e.g., WVE-006 for alpha-1 antitrypsin deficiency). Comparable as a platform-based oligonucleotide company pursuing extrahepatic tissues including muscle.
  • Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies and small molecules for cardiomyopathies and heart failure. Comparable to Soufflé's PLN cardiomyopathy program given overlapping cardiac indication and rare genetic heart disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights6 records

Customer concentration

Soufflé Therapeutics social profiles

Digital presence

Soufflé Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Soufflé Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Soufflé Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Soufflé Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soufflé Therapeutics

What does Soufflé Therapeutics do?

Soufflé Therapeutics engineers cell-specific ligands to deliver siRNA-based genetic medicines precisely across cell membranes into target cells such as cardiomyocytes and skeletal muscle cells. The company combines proprietary technologies for cell-specific receptor identification, ligand optimization, and potent siRNA engineering to develop therapies addressing rare genetic diseases and broader metabolic disorders. Initial programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated cardiomyopathies, with clinical trials planned to begin in 2026.

Is Soufflé Therapeutics a public or private company?

Soufflé Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Soufflé Therapeutics founded?

Soufflé Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Soufflé Therapeutics based?

Soufflé Therapeutics is headquartered in Boston, United States, in the North America region.

How does Soufflé Therapeutics make money?

Two revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are future Product Sales.

Who are Soufflé Therapeutics's main competitors?

Broad incumbents on record are Novo Nordisk, Ionis Pharmaceuticals, CRISPR Therapeutics and Sarepta Therapeutics. Direct peers are Verve Therapeutics, Intellia Therapeutics, Arrowhead Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Wave Life Sciences and Tenaya Therapeutics.

Does Soufflé Therapeutics have an API?

No public API is recorded for Soufflé Therapeutics.

What industry is Soufflé Therapeutics in?

Soufflé Therapeutics's product category is RNA-based Genetic Medicines. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAADAB, siRNA Therapeutics (gene silencing). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Soufflé Therapeutics Raises $135 Million Series B Led By Juvia Group To Advance Clinical PipelineSoufflé Therapeutics closed a $135 million Series B led by Juvia Group to advance its RNA therapeutics platform. The funds will support first clinical studies in facioscapulohumeral muscular dystrophy, heart failure, and muscle disorders. The company's lead program targets FSHD, a disease with no approved disease-modifying therapies.VC News DailySouffle Therapeutics Nets $135M Series BSouffle Therapeutics closed an oversubscribed $135 million Series B financing led by Juvia Group. The round includes institutional investors such as TCG Crossover Management, BB Biotech, Fidelity, and Balyasny, plus existing investors like Amgen Ventures and ARCH Venture Partners.citybizSoufflé Therapeutics Raises $135M to Advance RNA Delivery PlatformSoufflé Therapeutics raised $135 million in Series B financing led by Juvia Group to advance its RNA delivery platform. The company will use the funds to move its first three programs into human studies, targeting FSHD, heart failure, and metabolic disease. The next test is whether its receptor-targeting strategy translates into clinical data.TechStartupsStartup Funding News Today, October 14, 2026: Allara, ICON, Pluto Security, Soufflé Therapeutics, SUNMMIO & MoreOn October 14, 2026, eight startups disclosed funding rounds totaling $503.5 million, with ICON raising $200 million and Soufflé Therapeutics $135 million. The rounds span construction robotics, RNA therapeutics, AI chips, and healthcare AI, with seven U.S. companies and two Chinese firms. Investors are backing technologies tied to expensive problems in the physical world.The Pharma LetterSoufflé Therapeutics raises $135 million Series B to take extra-hepatic RNA therapies into clinicSoufflé Therapeutics closed a $135 million Series B led by Juvia Group to fund first clinical studies in facioscapulohumeral muscular dystrophy, heart failure, and muscle and metabolic disorders. New investors include TCG Crossover Management, BB Biotech, Fidelity, Balyasny, and an unnamed sovereign wealth fund.The future of tradingSoufflé Therapeutics closes oversubscribed $135 million Series B backed by Safar PartnersSoufflé Therapeutics closed an oversubscribed $135 million Series B on Oct. 13, 2026, with Safar Partners as an existing investor. The RNA therapies company will use the funds to advance three lead programs into clinical studies, including candidates for FSHD and heart failure with reduced ejection fraction.MarketScreenerSoufflé Therapeutics, Inc. announced that it has received $135 million in funding from a group of investorsSoufflé Therapeutics announced a $135 million funding round led by Juvia Group on October 13, 2026. The round included participation from TCG Crossover, BB Biotech Ventures, Fidelity, Balyasny, and others, with convertible preferred shares issued.Business Wire BlogSoufflé Therapeutics™ Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline ProgressSoufflé Therapeutics closed an oversubscribed $135 million Series B financing led by Juvia Group. Proceeds will fund first clinical studies in facioscapulohumeral muscular dystrophy, heart failure, and muscle and metabolic disorders. The company's REMEDY platform enables cell-specific delivery of oligonucleotide therapies.Startup ResearcherSoufflé Therapeutics Closes Oversubscribed $135 Million Series B FinancingSoufflé Therapeutics closed an oversubscribed $135 million Series B on October 13, 2026, led by Juvia Group. The funding will support its first clinical studies, including programs for facioscapulohumeral muscular dystrophy and heart failure. The company's REMEDY platform enables cell-specific delivery of oligonucleotide therapies.MITBig strides in cancer detection and treatment from the tiniest technologiesThe MIT Marble Center for Precision Cancer Medicine celebrated its 10th anniversary on April 9 with talks by director Sangeeta Bhatia and founding member Robert Langer, along with a panel discussion featuring center spinout founders. The event highlighted a decade of progress in turning nanotechnology innovations into commercial cancer detection and treatment technologies. Panel participants from spinouts including Matrisone Bio, Elicio Therapeutics, Soufflé Therapeutics, and Amplifyer Bio shared insights on the challenges and rewards of translating lab discoveries into market-ready technologies.